RECURSION PHARMACEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $1.92B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | Before market open | $7.70M | $-0.25 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | Before market open | $6.50M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 25, 2026 | Before market open | $35.50M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | $5.20M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | $19.20M | $-0.41 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 5, 2025 | Before market open | $15.00M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 28, 2025 | Before market open | $4.50M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | After market close | $26.10M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| cash operating expensenon-GAAP | full year 2026 | $375.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Recursion Pharmaceuticals filed with the SEC
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
REC-4881 MEK1/2 Translating proof to products
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
REC-4881 MEK1/2 Translating proof to products
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Earnings 2Q26 AUGUST 5, 2026
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Recursion Reports First Quarter Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Earnings 1Q26 MAY 6, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Wholly Owned Clinical Pipeline Translate insights ➔ proof points ➔ new medicines
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
OUR MISSION: Decoding biology to radically improve lives
Regulation FD disclosure · EX-99.1 to Form 8-K
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Decoding Biology To Radically Improve Lives November 2025 - Corporate Presentation
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Recursion exists to find a better way to discover and develop new medicines 3 Biology is extraordinarily complex; we understand only a small fraction of how it functions
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Building Momentum: Portfolio Advancement Fueled by Platform Insights
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral
Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Important Information This presentation of Recursion Pharmaceuticals,
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Recursion 0.1 e.g.: FAP Phenomics SiRNA Repurposing 5
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Decoding Biology To Radically Improve Lives FEBRUARY 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Recursion is on the frontier of TechBio Leading Indicators in 2024 to a Cascade of Proof Points in 2025
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Decoding Biology to Radically Improve Lives JANUARY 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
NOVEMBER 2024 Decoding Biology To Radically Improve Lives
Acquisition or disposition completed · Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
Acquisition or disposition completed · Executive or director change · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive (Loss)/Income for the three and nine months ended September 30, 2024 and 2023
Acquisition or disposition completed · Executive or director change · Regulation FD disclosure · Other events · EX-99.4 to Form 8-K
Recursion and Exscientia Shareholders Approve the Proposed Combination
Other events · EX-99.1 to Form 8-K
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
November 2024 Decoding Biology To Radically Improve Lives
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
Regulation FD disclosure · EX-99.1 to Form 8-K
October 2024 Decoding Biology To Radically Improve Lives
Regulation FD disclosure · EX-99.2 to Form 8-K
September 2024 Decoding Biology To Radically Improve Lives
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K